These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30385823)

  • 1. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
    Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.
    Dawson H; Grundmann S; Koelzer VH; Galván JA; Kirsch R; Karamitopoulou E; Lugli A; Inderbitzin D; Zlobec I
    Histopathology; 2015 Apr; 66(5):715-25. PubMed ID: 25382057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined epithelial marker analysis of tumour budding in stage II colorectal cancer.
    Slik K; Blom S; Turkki R; Välimäki K; Kurki S; Mustonen H; Haglund C; Carpén O; Kallioniemi O; Korkeila E; Sundström J; Pellinen T
    J Pathol Clin Res; 2019 Jan; 5(1):63-78. PubMed ID: 30358171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    De Smedt L; Palmans S; Andel D; Govaere O; Boeckx B; Smeets D; Galle E; Wouters J; Barras D; Suffiotti M; Dekervel J; Tousseyn T; De Hertogh G; Prenen H; Tejpar S; Lambrechts D; Sagaert X
    Br J Cancer; 2017 Jan; 116(1):58-65. PubMed ID: 27884016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.
    Rieger G; Koelzer VH; Dawson HE; Berger MD; Hädrich M; Inderbitzin D; Lugli A; Zlobec I
    Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer.
    Koelzer VH; Karamitopoulou E; Dawson H; Kondi-Pafiti A; Zlobec I; Lugli A
    Br J Cancer; 2013 May; 108(10):2088-96. PubMed ID: 23632477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor budding and human chorionic gonadotropin-β expression correlate with unfavorable patient outcome in colorectal carcinoma.
    Konishi Y; Kawamata F; Nishihara H; Homma S; Kato Y; Tsuda M; Kohsaka S; Einama T; Liu C; Yoshida T; Nagatsu A; Tanino M; Tanaka S; Kawamura H; Kamiyama T; Taketomi A
    Med Oncol; 2018 Jun; 35(7):104. PubMed ID: 29892782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour budding in solid cancers.
    Lugli A; Zlobec I; Berger MD; Kirsch R; Nagtegaal ID
    Nat Rev Clin Oncol; 2021 Feb; 18(2):101-115. PubMed ID: 32901132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
    Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
    Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
    Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
    Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
    Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
    Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma.
    Jensen DH; Dabelsteen E; Specht L; Fiehn AM; Therkildsen MH; Jønson L; Vikesaa J; Nielsen FC; von Buchwald C
    J Pathol; 2015 Aug; 236(4):505-16. PubMed ID: 25925492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships among
    Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
    World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive power of tumour budding for lymph node metastasis in colorectal carcinomas: A retrospective study.
    Deb B; Jacob SE
    Indian J Med Res; 2019 Dec; 150(6):635-639. PubMed ID: 32048628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation status and consensus molecular subtypes of colorectal cancer in patients from Rwanda.
    Nzitakera A; Uwamariya D; Kato H; Surwumwe JB; Mbonigaba A; Ndoricyimpaye EL; Uwamungu S; Manirakiza F; Ndayisaba MC; Ntakirutimana G; Seminega B; Dusabejambo V; Rutaganda E; Kamali P; Ngabonziza F; Ishikawa R; Watanabe H; Rugwizangoga B; Baba S; Yamada H; Yoshimura K; Sakai Y; Sugimura H; Shinmura K
    BMC Cancer; 2024 Oct; 24(1):1266. PubMed ID: 39394554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.